Pulmonology · Medical Literature
COPD Patients with a High Exacerbation Risk: Baseline Data Analysis of a National Chinese Prospective Multi-Center Study of Quality Improvement Project.
Abstract
Patients with chronic obstructive pulmonary disease (COPD) with a history of frequent exacerbations have a high disease burden and poor progression, demanding optimized management. This study aimed to evaluate the real-world clinical situation, adherence to Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations, and the associated factors. We conducted a cross-sectional analysis of baseline data from the national multi-center Quality Improvement Program, which enrolled 1055 COPD patients with a high exacerbation risk from 40 hospitals across five geographic regions in China (NCT05638646). Patient characteristics, disease burden, management patterns and the associated factors were analyzed. The study population had a mean age of 66.2 years, and 85.6% were male. Most patients had substantial disease burden, with 43.3% classified as GOLD stages 3-4 and 93.6% categorized into GOLD group E. In previous 12 months, 39.0% and 67.2% of these patients experienced at least one moderate or severe exacerbation, respectively. Overall, 75.1% received maintenance therapy using long-acting bronchodilators, but only 17.7% were receiving maintenance therapy consistent with the GOLD recommendations for initial treatment. Among patients receiving inhaled therapy, 70.9% initiated maintenance therapy within one month after diagnosis, whereas the self-reported good compliance was only 47.3%. Despite most patients received inhalation technique checks and education, only 61.9% can use the inhalation device appropriately, as evaluated by research team. Hospital level, hospital region, availability of blood eosinophil counts, and disease severity were significantly associated with the management patterns. COPD patients with a high exacerbation risk in China had a substantial disease burden and important gaps between real-world management patterns and GOLD recommendations. These findings suggest opportunities to improve guideline implementation, particularly in secondary and county-based hospitals. Future studies should evaluate whether targeted quality improvement interventions can improve patient outcomes. NCT05638646.
Clinical relevance
Among COPD patients with a high exacerbation risk in China, what is the real-world disease burden, the degree of adherence to GOLD pharmacological recommendations, and what patient- and system-level factors are associated with management patterns? __SNAPSHOT__ {"studyDesign":"Cross-sectional analysis of baseline data from a national prospective multicenter Quality Improvement Program (registered: NCT05638646)","setting":"40 hospitals across five geographic regions in China, spanning multiple hospital levels (secondary and tertiary); institutional types not individually described beyond hospital level","sampleSize":"n = 1,055 (single-arm observational cohort; no comparator group)","population":"Adults with spirometry-confirmed COPD classified as high exacerbation risk (GOLD group E by 2023 GOLD criteria). Mean age 66.2 years; 85.6% male. Patients already receiving regular triple therapy and those with particularly severe disease were excluded to facilitate evaluation of a subsequent intervention phase.","intervention":"No experimental intervention at this baseline phase; observational characterization of real-world clinical status, treatment patterns, and GOLD guideline adherence","comparator":"Not applicable (single-arm cross-sectional baseline analysis)","primaryOutcome":"Proportion of patients receiving maintenance therapy consistent with GOLD recommendations for initial pharmacological treatment; characterization of disease burden and management patterns; identification of factors associated with management patterns","followUp":"Not applicable (cross-sectional baseline analysis; prospective intervention phase ongoing)","fundingSource":"Not reported in abstract or available full-text excerpt"}
Key findings
Of 1,055 high-exacerbation-risk COPD patients, the disease burden was substantial: 43.3% were GOLD spirometric stages 3–4, and 93.6% were classified into GOLD group E. In the preceding 12 months, 39.0% had experienced at least one moderate exacerbation and 67.2% at least one severe exacerbation. Regarding pharmacological management, 75.1% received maintenance therapy with long-acting bronchodilators; however, only 17.7% were receiving therapy consistent with GOLD recommendations for initial treatment — representing a guideline-adherence gap of approximately 57 percentage points among those on maintenance therapy (calculated). Among patients receiving inhaled therapy, 70.9% initiated maintenance therapy within one month of diagnosis, while self-reported good compliance was only 47.3%. Despite the majority receiving inhalation technique education and checks, only 61.9% could use their inhalation device appropriately as assessed by the research team. Nearly 30% of patients experienced delayed treatment initiation after diagnosis. Hospital level, geographic region, availability of blood eosinophil counts, and disease severity were significantly associated with management patterns. No p-values, confidence intervals, odds ratios, or NNT/NNH values were reported in the available abstract or excerpt.
Practice implications
This study establishes a striking and clinically important gap between real-world COPD management and evidence-based GOLD recommendations in Chinese patients at highest exacerbation risk. Although three-quarters received some form of long-acting bronchodilator therapy, fewer than one in five received therapy aligned with current GOLD initial treatment guidance — a finding with direct implications for exacerbation prevention and disease progression. The observation that nearly 30% experienced delayed treatment initiation further compounds cumulative disease burden in this population. Critically, system-level factors — hospital tier, geographic region, and availability of blood eosinophil testing — were independently associated with treatment patterns, highlighting structural and resource inequities within China's tiered healthcare system as key drivers of undertreatment. These findings apply specifically to high-exacerbation-risk (GOLD group E) COPD patients at hospital-based centers in China and cannot be directly generalized to community settings, primary care, or non-Chinese populations. Patients already on triple therapy and those with particularly severe disease were excluded, potentially underestimating the full scope of the treatment gap. Because this is baseline cross-sectional data from a quality improvement program with no control group, no causal inferences about the consequences of non-adherence can be drawn from this analysis alone. As only an abstract and partial full-text were available, additional details (regression coefficients, multivariable model structure, and funding sources) could not be verified. __LIMITATIONS__ Cross-sectional design precludes causal inference; no longitudinal clinical outcomes (exacerbation rates, mortality) are reported at this stage.,Selection bias: exclusion of patients already on triple therapy and those with particularly severe disease may underrepresent the most undertreated and highest-burden patients.,GOLD adherence rate must be interpreted with caution in patients with prior treatment histories, as GOLD recommendations are intended to guide initial rather than escalation therapy.,The COPD diagnosis date was defined as the date of first spirometry-confirmed diagnosis, potentially underestimating treatment delays if clinical diagnosis preceded spirometry.,Self-reported compliance (47.3%) relies on patient recall and is subject to social desirability bias; no objective adherence metric (e.g., pharmacy refill data) was described.,No p-values, confidence intervals, or effect sizes were reported in the available abstract for the association analyses, limiting assessment of statistical precision.,Generalizability is limited to hospital-based COPD populations in China; findings likely do not reflect primary care or community management nationwide.,Funding source is not reported, precluding assessment of potential conflicts of interest.,Male predominance (85.6%) limits applicability to women with COPD. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In a large, nationally representative Chinese cohort of high-exacerbation-risk COPD patients, fewer than one in five received pharmacotherapy consistent with GOLD guidelines, despite three-quarters being on some maintenance therapy — a clinically important gap driven in part by hospital level, geographic region, and access to eosinophil testing. Inhalation technique was inadequate in nearly 40% of patients assessed, and roughly 30% had delayed treatment initiation. These findings do not yet call for changes in individual prescribing practice but are a strong signal for health system interventions, including improved clinician education, standardized access to eosinophil testing, and structured inhaler training programs, particularly at secondary and regional hospitals.